Skip to content
OpenCapital
Get started

Eli Lilly LLY Mounjaro — Revenue

Other product segments

Zepbound
$4.16B+79.9%
Verzenio
$1.3B+12.3%
Jardiance
$1.11B+9.9%
Other oncology
$966M+22.4%
Trulicity
$919M-16.1%
Other cardiometabolic health
$905M-4.2%
Taltz
$733M-3.8%
Other immunology
$470M+44.2%
Neuroscience
$382M+40.4%

Similar metrics at other companies

RFL
RFLProduct Revenue — Revenue
$89K-63.4%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Cumberland Pharmaceuticals logo
CPIXProduct — Revenue
$10.1M+10.6%
Aurinia Pharmaceuticals logo
AUPHU.S. — Revenue
$65.96M+25.6%
CorMedix logo
CRMDProduct sales, net — Total Revenue
$121.92M+212%
Theravance Biopharma logo
TBPHYupelri Monotherapy — Revenue
$21.85M+7.0%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's mounjaro — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's mounjaro — revenue?
Eli Lilly (LLY) reported mounjaro — revenue of $8.66B in Q1 2026.
How has Eli Lilly's mounjaro — revenue changed year-over-year?
Eli Lilly's mounjaro — revenue increased by 125.5% year-over-year, from $3.84B to $8.66B.
What is the long-term trend for Eli Lilly's mounjaro — revenue?
Over 3 years (2022 to 2025), Eli Lilly's mounjaro — revenue has grown at a 262.4% compound annual growth rate (CAGR), from $482.6M to $22.97B.
What does mounjaro — revenue mean?
This metric represents the total gross sales generated from the specific pharmaceutical product line dedicated to cardiometabolic treatments. It reflects the market adoption, pricing power, and commercial success of the drug within its therapeutic category. Monitoring this figure provides insight into the company's ability to scale high-growth assets and capture market share in competitive healthcare segments.